BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Parrish KE, Pokorny J, Mittapalli RK, Bakken K, Sarkaria JN, Elmquist WF. Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model. J Pharmacol Exp Ther 2015;355:264-71. [PMID: 26354993 DOI: 10.1124/jpet.115.228213] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 8.6] [Reference Citation Analysis]
Number Citing Articles
1 Chaturvedi S, Rashid M, Malik MY, Agarwal A, Singh SK, Gayen JR, Wahajuddin M. Neuropharmacokinetics: a bridging tool between CNS drug development and therapeutic outcome. Drug Discov Today 2019;24:1166-75. [PMID: 30898661 DOI: 10.1016/j.drudis.2019.02.007] [Reference Citation Analysis]
2 Fu H, Wu ZX, Lei ZN, Teng QX, Yang Y, Ashby CR, Lei Y, Lian Y, Chen ZS. The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter. Front Pharmacol 2022;13:861642. [PMID: 35350768 DOI: 10.3389/fphar.2022.861642] [Reference Citation Analysis]
3 de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, van Tellingen O. Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2. Neoplasia 2018;20:710-20. [PMID: 29852323 DOI: 10.1016/j.neo.2018.05.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
4 Gupta SK, Smith EJ, Mladek AC, Tian S, Decker PA, Kizilbash SH, Kitange GJ, Sarkaria JN. PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity. Front Oncol 2018;8:670. [PMID: 30723695 DOI: 10.3389/fonc.2018.00670] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
5 Gampa G, Vaidhyanathan S, Resman BW, Parrish KE, Markovic SN, Sarkaria JN, Elmquist WF. Challenges in the delivery of therapies to melanoma brain metastases. Curr Pharmacol Rep 2016;2:309-25. [PMID: 28546917 DOI: 10.1007/s40495-016-0072-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
6 Rathi S, Griffith JI, Zhang W, Zhang W, Oh JH, Talele S, Sarkaria JN, Elmquist WF. The influence of the blood-brain barrier in the treatment of brain tumours. J Intern Med 2022. [PMID: 35040235 DOI: 10.1111/joim.13440] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Gomez-Zepeda D, Taghi M, Scherrmann JM, Decleves X, Menet MC. ABC Transporters at the Blood-Brain Interfaces, Their Study Models, and Drug Delivery Implications in Gliomas. Pharmaceutics 2019;12:E20. [PMID: 31878061 DOI: 10.3390/pharmaceutics12010020] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
8 Hartz AMS, Schulz JA, Sokola BS, Edelmann SE, Shen AN, Rempe RG, Zhong Y, Seblani NE, Bauer B. Isolation of Cerebral Capillaries from Fresh Human Brain Tissue. J Vis Exp 2018. [PMID: 30272660 DOI: 10.3791/57346] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
9 Blethen KE, Arsiwala TA, Fladeland RA, Sprowls SA, Panchal DM, Adkins CE, Kielkowski BN, Earp LE, Glass MJ, Pritt TA, Cabuyao YM, Aulakh S, Lockman PR. Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases. Neurooncol Adv 2021;3:v133-43. [PMID: 34859240 DOI: 10.1093/noajnl/vdab123] [Reference Citation Analysis]
10 Olmez I, Brenneman B, Xiao A, Serbulea V, Benamar M, Zhang Y, Manigat L, Abbas T, Lee J, Nakano I, Godlewski J, Bronisz A, Abounader R, Leitinger N, Purow B. Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms. Clin Cancer Res 2017;23:6958-68. [PMID: 28814434 DOI: 10.1158/1078-0432.CCR-17-0803] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 8.6] [Reference Citation Analysis]
11 Cook Sangar ML, Genovesi LA, Nakamoto MW, Davis MJ, Knobluagh SE, Ji P, Millar A, Wainwright BJ, Olson JM. Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models. Clin Cancer Res 2017;23:5802-13. [PMID: 28637687 DOI: 10.1158/1078-0432.CCR-16-2943] [Cited by in Crossref: 37] [Cited by in F6Publishing: 21] [Article Influence: 7.4] [Reference Citation Analysis]
12 Murphy CG. The Role of CDK4/6 Inhibitors in Breast Cancer. Curr Treat Options Oncol 2019;20:52. [PMID: 31101994 DOI: 10.1007/s11864-019-0651-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
13 Cai S, Wang J, Zeng W, Cheng X, Liu L, Li W. Lysine-specific histone demethylase 1B (LSD2/KDM1B) represses p53 expression to promote proliferation and inhibit apoptosis in colorectal cancer through LSD2-mediated H3K4me2 demethylation. Aging (Albany NY) 2020;12:14990-5001. [PMID: 32726297 DOI: 10.18632/aging.103558] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Edessa D, Sisay M. Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib. Breast Cancer (Dove Med Press) 2017;9:567-79. [PMID: 29263697 DOI: 10.2147/BCTT.S150540] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
15 de Gooijer MC, Zhang P, Weijer R, Buil LCM, Beijnen JH, van Tellingen O. The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer 2018;142:381-91. [PMID: 28921565 DOI: 10.1002/ijc.31052] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
16 Ehab M, Elbaz M. Profile of palbociclib in the treatment of metastatic breast cancer. Breast Cancer (Dove Med Press) 2016;8:83-91. [PMID: 27274308 DOI: 10.2147/BCTT.S83146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
17 Yadav P, Shah K. An overview on synthetic and pharmaceutical prospective of pyrido[2,3-d]pyrimidines scaffold. Chem Biol Drug Des 2021;97:633-48. [PMID: 32946161 DOI: 10.1111/cbdd.13800] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Robert M, Frenel J, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M. Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer. Expert Opinion on Drug Metabolism & Toxicology 2019;15:85-91. [DOI: 10.1080/17425255.2019.1559816] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Quader S, Kataoka K, Cabral H. Nanomedicine for brain cancer. Adv Drug Deliv Rev 2022;182:114115. [PMID: 35077821 DOI: 10.1016/j.addr.2022.114115] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
20 Sorf A, Hofman J, Kučera R, Staud F, Ceckova M. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. Biochemical Pharmacology 2018;154:10-7. [DOI: 10.1016/j.bcp.2018.04.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
21 Riess C, Irmscher N, Salewski I, Strüder D, Classen CF, Große-Thie C, Junghanss C, Maletzki C. Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma-backbone or add-on in immune-oncology? Cancer Metastasis Rev 2021;40:153-71. [PMID: 33161487 DOI: 10.1007/s10555-020-09940-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Corona SP, Generali D. Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer. Drug Des Devel Ther 2018;12:321-30. [PMID: 29497278 DOI: 10.2147/DDDT.S137783] [Cited by in Crossref: 43] [Cited by in F6Publishing: 25] [Article Influence: 10.8] [Reference Citation Analysis]
23 de Gooijer MC, Buil LCM, Beijnen JH, van Tellingen O. ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors. Invest New Drugs 2018;36:380-7. [DOI: 10.1007/s10637-017-0539-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 Robert M, Frenel JS, Bourbouloux E, Rigaud DB, Patsouris A, Augereau P, Gourmelon C, Campone M. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer. Drugs 2018;78:1353-62. [PMID: 30143968 DOI: 10.1007/s40265-018-0972-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Patel YT, Davis A, Baker SJ, Campagne O, Stewart CF. CNS penetration of the CDK4/6 inhibitor ribociclib in non-tumor bearing mice and mice bearing pediatric brain tumors. Cancer Chemother Pharmacol 2019;84:447-52. [PMID: 31079218 DOI: 10.1007/s00280-019-03864-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
26 Laramy JK, Kim M, Parrish KE, Sarkaria JN, Elmquist WF. Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier. J Pharmacol Exp Ther 2018;365:249-61. [PMID: 29440450 DOI: 10.1124/jpet.117.246116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
27 Marini BL, Benitez LL, Zureick AH, Salloum R, Gauthier AC, Brown J, Wu YM, Robinson DR, Kumar C, Lonigro R, Vats P, Cao X, Kasaian K, Anderson B, Mullan B, Chandler B, Linzey JR, Camelo-Piragua SI, Venneti S, McKeever PE, McFadden KA, Lieberman AP, Brown N, Shao L, Leonard MAS, Junck L, McKean E, Maher CO, Garton HJL, Muraszko KM, Hervey-Jumper S, Mulcahy-Levy JM, Green A, Hoffman LM, Dorris K, Vitanza NA, Wang J, Schwartz J, Lulla R, Smiley NP, Bornhorst M, Haas-Kogan DA, Robertson PL, Chinnaiyan AM, Mody R, Koschmann C. Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. Transl Res 2017;188:27.e1-27.e14. [PMID: 28860053 DOI: 10.1016/j.trsl.2017.08.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
28 Dash RP, Jayachandra Babu R, Srinivas NR. Therapeutic Potential and Utility of Elacridar with Respect to P-glycoprotein Inhibition: An Insight from the Published In Vitro, Preclinical and Clinical Studies. Eur J Drug Metab Pharmacokinet 2017;42:915-33. [PMID: 28374336 DOI: 10.1007/s13318-017-0411-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
29 Ivanyuk A, Livio F, Biollaz J, Buclin T. Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet 2017;56:825-92. [PMID: 28210973 DOI: 10.1007/s40262-017-0506-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 21.0] [Reference Citation Analysis]
30 Loretan L, Moskovszky LE, Kurrer M, Exner GU, Trojan A. Efficacy of a CDK4/6 Inhibitor in a Patient with Breast Cancer and Liposarcoma: A Case Report and Review of the Literature. Breast Care (Basel) 2019;14:325-8. [PMID: 31798393 DOI: 10.1159/000493370] [Reference Citation Analysis]
31 Fang Z, Chen L, Moser MAJ, Zhang W, Qin Z, Zhang B. Electroporation-Based Therapy for Brain Tumors: A Review. J Biomech Eng 2021;143:100802. [PMID: 33991087 DOI: 10.1115/1.4051184] [Reference Citation Analysis]
32 Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Shen Y, Feng Y, Protter AA, Elmquist WF, Sarkaria JN. Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Mol Cancer Ther 2017;16:2735-46. [PMID: 28947502 DOI: 10.1158/1535-7163.MCT-17-0365] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 5.4] [Reference Citation Analysis]
33 Jue TR, Mcdonald KL. The challenges associated with molecular targeted therapies for glioblastoma. J Neurooncol 2016;127:427-34. [DOI: 10.1007/s11060-016-2080-6] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 7.5] [Reference Citation Analysis]
34 Kim M, Kizilbash SH, Laramy JK, Gampa G, Parrish KE, Sarkaria JN, Elmquist WF. Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. Pharm Res 2018;35:177. [PMID: 30003344 DOI: 10.1007/s11095-018-2455-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
35 Tanaka T, Terai Y, Ashihara K, Fujiwara S, Tanaka Y, Sasaki H, Tsunetoh S, Ohmichi M. The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer. PLoS One 2017;12:e0177019. [PMID: 28472136 DOI: 10.1371/journal.pone.0177019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
36 Gampa G, Vaidhyanathan S, Sarkaria JN, Elmquist WF. Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities? Pharmacol Res 2017;123:10-25. [PMID: 28634084 DOI: 10.1016/j.phrs.2017.06.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
37 Lazow MA, Johnson SL, Johnson ND, Breneman JC, Dexheimer PJ, Szabo S, Pressey JG. Genome-Driven Therapy for Chemotherapy-Resistant Metastatic CDK6-Amplified Osteosarcoma. JCO Precis Oncol 2020;4:498-504. [PMID: 35050742 DOI: 10.1200/PO.20.00032] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
38 de Gooijer MC, Kemper EM, Buil LCM, Çitirikkaya CH, Buckle T, Beijnen JH, van Tellingen O. ATP-binding cassette transporters restrict drug delivery and efficacy against brain tumors even when blood-brain barrier integrity is lost. Cell Rep Med 2021;2:100184. [PMID: 33521698 DOI: 10.1016/j.xcrm.2020.100184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
39 de Gooijer MC, Buil LCM, Çitirikkaya CH, Hermans J, Beijnen JH, van Tellingen O. ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461. Mol Pharm 2018;15:5236-43. [PMID: 30252484 DOI: 10.1021/acs.molpharmaceut.8b00742] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
40 Whittaker S, Madani D, Joshi S, Chung SA, Johns T, Day B, Khasraw M, McDonald KL. Combination of palbociclib and radiotherapy for glioblastoma. Cell Death Discov 2017;3:17033. [PMID: 28690875 DOI: 10.1038/cddiscovery.2017.33] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
41 Schröder LB, McDonald KL. CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future? Front Oncol 2015;5:259. [PMID: 26649278 DOI: 10.3389/fonc.2015.00259] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
42 Banerjee K, Núñez FJ, Haase S, McClellan BL, Faisal SM, Carney SV, Yu J, Alghamri MS, Asad AS, Candia AJN, Varela ML, Candolfi M, Lowenstein PR, Castro MG. Current Approaches for Glioma Gene Therapy and Virotherapy. Front Mol Neurosci 2021;14:621831. [PMID: 33790740 DOI: 10.3389/fnmol.2021.621831] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Gowarty JL, Herrington JD. Verapamil as a culprit of palbociclib toxicity. J Oncol Pharm Pract 2019;25:743-6. [DOI: 10.1177/1078155218761798] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
44 Li J, Jiang J, Wu J, Bao X, Sanai N. Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment. Clin Pharmacol Ther 2021;109:494-506. [PMID: 32799335 DOI: 10.1002/cpt.2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Liu YW, Xia R, Lu K, Xie M, Yang F, Sun M, De W, Wang C, Ji G. LincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation. Mol Cancer. 2017;16:39. [PMID: 28209170 DOI: 10.1186/s12943-017-0588-9] [Cited by in Crossref: 86] [Cited by in F6Publishing: 92] [Article Influence: 17.2] [Reference Citation Analysis]
46 Heffron TP. Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. J Med Chem 2016;59:10030-66. [DOI: 10.1021/acs.jmedchem.6b00618] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 10.8] [Reference Citation Analysis]
47 Laramy JK, Kim M, Gupta SK, Parrish KE, Zhang S, Bakken KK, Carlson BL, Mladek AC, Ma DJ, Sarkaria JN, Elmquist WF. Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. J Pharmacol Exp Ther 2017;363:136-47. [PMID: 28847917 DOI: 10.1124/jpet.117.243477] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
48 Gupta P, Narayanan S, Yang D. CDK Inhibitors as Sensitizing Agents for Cancer Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Elsevier; 2019. pp. 125-49. [DOI: 10.1016/b978-0-12-816435-8.00009-2] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Gampa G, Kenchappa RS, Mohammad AS, Parrish KE, Kim M, Crish JF, Luu A, West R, Hinojosa AQ, Sarkaria JN, Rosenfeld SS, Elmquist WF. Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma. Sci Rep 2020;10:6524. [PMID: 32300151 DOI: 10.1038/s41598-020-63494-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Ghosh D, Nandi S, Bhattacharjee S. Combination therapy to checkmate Glioblastoma: clinical challenges and advances. Clin Transl Med 2018;7:33. [PMID: 30327965 DOI: 10.1186/s40169-018-0211-8] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 19.0] [Reference Citation Analysis]
51 Griffith JI, Rathi S, Zhang W, Zhang W, Drewes LR, Sarkaria JN, Elmquist WF. Addressing BBB Heterogeneity: A New Paradigm for Drug Delivery to Brain Tumors. Pharmaceutics 2020;12:E1205. [PMID: 33322488 DOI: 10.3390/pharmaceutics12121205] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
52 Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer 2018;18:452-64. [PMID: 29643473 DOI: 10.1038/s41568-018-0005-8] [Cited by in Crossref: 517] [Cited by in F6Publishing: 519] [Article Influence: 172.3] [Reference Citation Analysis]
53 Zhang D, Hop CECA, Patilea-Vrana G, Gampa G, Seneviratne HK, Unadkat JD, Kenny JR, Nagapudi K, Di L, Zhou L, Zak M, Wright MR, Bumpus NN, Zang R, Liu X, Lai Y, Khojasteh SC. Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities. Drug Metab Dispos 2019;47:1122-35. [PMID: 31266753 DOI: 10.1124/dmd.119.086744] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
54 Kim M, Ma DJ, Calligaris D, Zhang S, Feathers RW, Vaubel RA, Meaux I, Mladek AC, Parrish KE, Jin F, Barriere C, Debussche L, Watters J, Tian S, Decker PA, Eckel-Passow JE, Kitange GJ, Johnson AJ, Parney IF, Anastasiadis PZ, Agar NYR, Elmquist WF, Sarkaria JN. Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Mol Cancer Ther 2018;17:1893-901. [PMID: 29970480 DOI: 10.1158/1535-7163.MCT-17-0600] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
55 Miranda A, Blanco-prieto MJ, Sousa J, Pais A, Vitorino C. Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles. International Journal of Pharmaceutics 2017;531:389-410. [DOI: 10.1016/j.ijpharm.2017.07.049] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 6.2] [Reference Citation Analysis]
56 Mansfield AS, Ren H, Sutor S, Sarangi V, Nair A, Davila J, Elsbernd LR, Udell JB, Dronca RS, Park S, Markovic SN, Sun Z, Halling KC, Nevala WK, Aubry MC, Dong H, Jen J. Contraction of T cell richness in lung cancer brain metastases. Sci Rep 2018;8:2171. [PMID: 29391594 DOI: 10.1038/s41598-018-20622-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
57 Kizilbash SH, Gupta SK, Parrish KE, Laramy JK, Kim M, Gampa G, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Elmquist WF, Sarkaria JN. In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling. Mol Cancer Ther 2021;20:1009-18. [PMID: 33785646 DOI: 10.1158/1535-7163.MCT-20-0640] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Jove M, Spencer J, Hubbard M, Holden E, O’dea R, Brook B, Phillips R, Smye S, Loadman P, Twelves C. Cellular Uptake and Efflux of Palbociclib In Vitro in Single Cell and Spheroid Models. J Pharmacol Exp Ther 2019;370:242-51. [DOI: 10.1124/jpet.119.256693] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
59 Dong K, Yang X, Zhao T, Zhu X. An insight into the inhibitory selectivity of 4-(Pyrazol- 4-yl)-pyrimidines to CDK4 over CDK2. Molecular Simulation 2017;43:599-609. [DOI: 10.1080/08927022.2017.1279283] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]